These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 18338961)

  • 21. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients.
    Casado A; Consiglio E; Podzamczer D; Badia X
    HIV Clin Trials; 2001; 2(6):477-83. PubMed ID: 11742436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers.
    Castagna A; Danise A; Giudici B; Lazzarin A; Castelli F; Paraninfo G; Carosi G; Carriero PL
    J Chemother; 2002 Apr; 14(2):189-93. PubMed ID: 12017376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidisciplinary, inpatient directly observed therapy for HIV-1-infected children and adolescents failing HAART: A retrospective study.
    Parsons GN; Siberry GK; Parsons JK; Christensen JR; Joyner ML; Lee SL; Kiefner CM; Hutton N
    AIDS Patient Care STDS; 2006 Apr; 20(4):275-84. PubMed ID: 16623626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rate, causes, and clinical implications of presenting with low CD4+ cell counts in the era of highly active antiretroviral therapy.
    Núñez M; Asencio R; Valencia ME; Leal M; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2003 May; 19(5):363-8. PubMed ID: 12803995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia.
    Aboulafia DM; Bundow D; Waide S; Bennet C; Kerr D
    Am J Med Sci; 2000 Aug; 320(2):117-23. PubMed ID: 10981487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART.
    Guaraldi G; Murri R; Orlando G; Orlandi E; Sterrantino G; Borderi M; Grosso C; Cattelan AM; Nardini G; Beghetto B; Antinori A; Esposito R; Wu AW
    HIV Clin Trials; 2003; 4(2):99-106. PubMed ID: 12671777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.
    Nellen JF; Wit FW; De Wolf F; Jurriaans S; Lange JM; Prins JM
    J Acquir Immune Defic Syndr; 2004 Aug; 36(4):943-50. PubMed ID: 15220701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study.
    Kim KH; Yi J; Lee SH
    Korean J Intern Med; 2015 Sep; 30(5):705-13. PubMed ID: 26354065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.
    Yamashita TE; Phair JP; Muñoz A; Margolick JB; Detels R; O'Brien SJ; Mellors JW; Wolinsky SM; Jacobson LP
    AIDS; 2001 Apr; 15(6):735-46. PubMed ID: 11371688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death.
    Kitahata MM; Reed SD; Dillingham PW; Van Rompaey SE; Young AA; Harrington RD; Holmes KK
    Int J STD AIDS; 2004 Dec; 15(12):803-10. PubMed ID: 15601486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of adherence on CD4 cell count responses among HIV-infected patients.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2004 Mar; 35(3):261-8. PubMed ID: 15076240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
    Oyugi JH; Byakika-Tusiime J; Ragland K; Laeyendecker O; Mugerwa R; Kityo C; Mugyenyi P; Quinn TC; Bangsberg DR
    AIDS; 2007 May; 21(8):965-71. PubMed ID: 17457090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral adherence and use of alternative therapies among older HIV-infected adults.
    Wutoh AK; Brown CM; Kumoji EK; Daftary MS; Jones T; Barnes NA; Powell NJ
    J Natl Med Assoc; 2001; 93(7-8):243-50. PubMed ID: 11491273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.
    Li X; Chu H; Gallant JE; Hoover DR; Mack WJ; Chmiel JS; Muñoz A
    J Epidemiol Community Health; 2006 Sep; 60(9):811-8. PubMed ID: 16905728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.
    Tuboi SH; Harrison LH; Sprinz E; Albernaz RK; Schechter M
    J Acquir Immune Defic Syndr; 2005 Nov; 40(3):324-8. PubMed ID: 16249707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion.
    Thiébaut R; Jacqmin-Gadda H; Walker S; Sabin C; Prins M; Del Amo J; Porter K; Dabis F; Chêne G;
    HIV Med; 2006 Jan; 7(1):1-9. PubMed ID: 16313286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.
    Moore DM; Hogg RS; Yip B; Wood E; Tyndall M; Braitstein P; Montaner JS
    J Acquir Immune Defic Syndr; 2005 Nov; 40(3):288-93. PubMed ID: 16249702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.